EGFR and non-small cell lung carcinoma: To explore potential mechanisms underlying the effects of gut microbiota and fecal metabolites on immunotherapy efficacy in patients with advanced EGFR + NSCLC, correlation analysis between differentially abundant gut microbiota and metabolites at baseline in responders and non-responders showed significant associations (Fig. 6).